ASX News
Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Corporate Spotlight
An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight
RCE receives grant from US Department of Defence
Latest Threads
See All Discussions
Corporate Spotlight
Timeline
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $120.5M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 52.0¢ | 51.5¢ | $13.61K | 26.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1580 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 14897 | 2 |
View Market Depth
| Last trade - 15.58pm 07/10/2024 (20 minute delay) ? |
|
|||||
|
Last
52.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 52.0¢ | 52.0¢ | 52.0¢ | 465 | ||
| Last updated 10.42am 07/10/2024 ? | |||||
| RCE (ASX) Chart |
